Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LAZR vs SGMO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–3 Matrix Metrics)

SGMO Overall Winner 6-Pillar Tally: LAZR 2 – 4 SGMO Matrix Metrics: LAZR 3 – 6 SGMO

As of Nov 16, 2026, Sangamo Therapeutics, Inc. (SGMO) is the stronger overall head-to-head candidate over Luminar Technologies, Inc. (LAZR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). LAZR carries a Unified Composite Score of 46.3/100 (HOLD) at $27.12 (N/M Forward P/E, -340.9% operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin).

  • Technical & Structure Timing Caution: LAZR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LAZR vs SGMO
LAZR NASDAQ
Luminar Technologies, Inc. Class A Common Stock
Motor Vehicle Parts & Accessories
$27.12
-7.28% 1D
Market Cap $14.7M
TTM Revenue $76M
Forward P/E N/M
Beta / 30D Vol 3.66β · 99% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 58.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $32.28 · SMA50: $39.09
SGMO NASDAQ Head-to-Head Winner
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31

6-Pillar Scorecard Institutional Category Breakdown (LAZR 2 – 4 SGMO)

Columns: Metric · LAZR · SGMO
1. Valuation Multiples SGMO
Forward P/E N/M 0.4x
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue 0.2x 1.2x
2. Growth & Scale SGMO
Revenue Growth (YoY) +21.0% +88.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $76M $40M
Market Cap $14.7M $55.9M
3. Profitability & Quality LAZR
Gross Margin -15.1% N/A
Operating Margin -340.9% -175.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -2424.7% -2891.8%
4. Balance Sheet & Cash Flow SGMO
Cash Generation (TTM) -$222M EBITDA -$90M
Cash Flow Margin N/A N/A
Net Cash / Leverage -2424.7% ROE $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 80.3% (8th %ile) 144.2% (71st %ile)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat LAZR
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Motor Vehicle Parts & Accessories Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LAZR (3) vs SGMO (6)
Institutional Metric LAZR SGMO Criterion Row Edge
Market Capitalization
Scale
$14.7M $55.9M Larger Scale SGMO
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY)
Growth
+21.0% +88.4% Higher Growth SGMO
Operating Margin (TTM)
Profitability
-340.9% -175.5% Higher Margin SGMO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-2424.7% -2891.8% Higher ROE LAZR
52-Week Range Position
Momentum
53% ($0–$51) 9% ($0–$1) Stronger Trend LAZR
Beta / 30D Volatility
Risk Regime
3.66β · 99% Vol 1.49β · 206% Vol Lower Realized Risk LAZR
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 52.0 / 100 (HOLD) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
$76M $40M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-15.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · 1.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$222M EBITDA (-2424.7% ROE) -$90M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGMO +80.56 pp
LAZR: -78.27% · SGMO: +2.29%
3M Horizon SGMO +68.3 pp
LAZR: -91.63% · SGMO: -23.33%
6M Horizon SGMO +67.51 pp
LAZR: -93.09% · SGMO: -25.58%
1Y Horizon SGMO +94.98 pp
LAZR: -96.1% · SGMO: -1.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LAZR vs SGMO. Trailing 12-month operating profitability (LAZR -340.9% vs SGMO -175.5%) and valuation multiples (LAZR N/M vs SGMO 0.4x Forward P/E) are benchmarked directly in Pillar 4 below.

LAZR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin-15.1%
Op. Margin-340.9%
ROE / Fwd P/E-2424.7% · N/M
SGMO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross MarginN/A
Op. Margin-175.5%
ROE / Fwd P/E-2891.8% · 0.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LAZR BREAKDOWN
97d in phase · OBV NEUTRAL
Current IV 80.3%
IV Percentile 8th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LAZR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LAZR Moat Profile Cyclical / Execution-Driven Positioning
Motor Vehicle Parts & Accessories Operator
Competes within the Motor Vehicle Parts & Accessories value chain with $14.7M market capitalization and -340.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · Autonomous Vehicles / LiDAR
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LAZR vs SGMO Key Questions & Quantitative Answers

As of Nov 16, 2026, Sangamo Therapeutics, Inc. (SGMO) is the stronger overall head-to-head candidate over Luminar Technologies, Inc. (LAZR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). LAZR carries a Unified Composite Score of 46.3/100 (HOLD) at $27.12 (N/M Forward P/E, -340.9% operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin). Technical & Structure Timing Caution: LAZR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMO leads the Growth & Scale pillar: LAZR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (-15.1% gross margin, -340.9% operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). On trailing 12-month operating scale, LAZR generates $76M in USD-normalized revenue versus $40M for SGMO. In operating R&D and SG&A reinvestment, LAZR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.

SGMO screens cheaper on headline valuation multiples. LAZR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (unreported EBITDA margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LAZR (-2424.7% ROE) versus SGMO (-2891.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LAZR carries 80.3% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.66β · 99% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.